Pharmakogenetik – ein Schritt zur individualisierten Schmerzmedizin

Pharmacogenetics represents an important milestone on the path to individualized medicine. For pain therapy, polymorphisms that influence enzyme activity (CYP2D6, CYP2C9) and transporters (P-glycoprotein), as well as mutations that affect receptor density, are particularly relevant. Medications from the nonsteroidal anti-inflammatory drugs (NSAID) group as well as opiate therapy are affected by these polymorphisms.